Peptides that bind to and are presented by MHC class I and class II molecules collectively make up the immunopeptidome. In the context of vaccine development, an understanding of the immunopeptidome is essential, and much effort has been dedicated to its accurate and costeffective identification. Current state-of-the-art methods mainly comprise in silico tools for predicting MHC binding, which is strongly correlated with peptide immunogenicity. However, only a small proportion of the peptides that bind to MHC molecules are, in fact, immunogenic, and substantial work has been dedicated to uncovering additional determinants of peptide immunogenicity. In this context, and in light of recent advancements in mass spectrometry (MS), the existence of immunological hotspots has been given new life, inciting the hypothesis that hotspots are associated with MHC class I peptide immunogenicity. We here introduce a precise terminology for defining these hotspots and carry out a systematic analysis of MS and in silico predicted hotspots. We find that hotspots defined from MS data are largely captured by peptide binding predictions, enabling their replication in silico. This leads us to conclude that hotspots, to a great degree, are simply a result of promiscuous HLA binding, which disproves the hypothesis that the identification of hotspots provides novel information in the context of immunogenic peptide prediction. Furthermore, our analyses demonstrate that the signal of ligand processing, although present in the MS data, has very low predictive power to discriminate between MS and in silico defined hotspots.
Introduction
T cells of the cellular immune system monitor the health status of host cells by scrutinizing peptides presented on the cell surface in complex with MHC molecules. The collective set of peptides presented by MHC class I and class II molecules (MHC ligands) make up the immunopeptidome. The recognition of such peptides by T cells leads to the triggering of an immune response. An in-depth understanding of the immunopeptidome is therefore of fundamental importance for the development of vaccines and immunotherapies targeting infectious diseases and cancers. [1] [2] [3] Given this, great effort has been dedicated to the development of methods for accurate and cost-effective identification of the immunopeptidome. One such method is in silico MHC binding prediction, and the development of such tools has progressed substantially over the last decades, with current state-of-theart methods having accuracies comparable to the experimental variation between independent experimental laboratory measurements. 4 However, despite the established fact that there is a correlation between binding to MHC Abbreviations: HLA, human leucocyte antigen; IEDB, immune epitope database and analysis resource; MS, mass spectrometry. 
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and peptide immunogenicity, predicting the immunogenicity of predicted MHC class I binders remains a central challenge. [5] [6] [7] A peptide predicted to bind an MHC class I molecule is not naturally a T cell epitope, 5, 6 and only a small proportion of the peptides measured or predicted to bind to an MHC molecule are immunogenic. [7] [8] [9] This realization has spurred interest in investigating additional determinants of peptide immunogenicity with features such as antigen processing and MHC binding stability being of interest for evaluation. 6, 7 An additional factor that has been hypothesized to be associated with MHC class I peptide immunogenicity is immunological hotspots; regions in a protein that are particularly enriched in MHC ligands. 10 These hotspot regions of high MHC ligand concentration have been defined in a multiplicity of ways in various studies within a range of biological areas. 2, 5, [10] [11] [12] Most studies simply define hotspots as clusters of, ideally promiscuous, MHC class I binding peptides; 2, 3, 10, 11 however, for the more detailed studies, an immunological hotspot is defined as a region with a certain density of epitopes within a given protein sequence and with a defined minimum of overlapping peptides in the given region. 5, 12 Hotspots were initially studied in the context of infectious diseases and intracellular pathogens, most prominently in relation to human immunodeficiency virus 1 (HIV-1). In fact, the first reports on HIV-1 epitope clustering in proteins were published only shortly after the discovery of the epitopes themselves. [12] [13] [14] In these studies, hotspots were generated based on predicting high-affinity MHC class I binders using available prediction algorithms. However, the extent to which HIV-1 epitopes clustered was not rigorously investigated until recently, when Schmid et al. 12 found that the epitope distribution in > 99% of protein sequences did not differ from random. In the context of infectious diseases, hotspots predicted based on human leucocyte antigen (HLA) I affinity binding prediction tools are used mainly to visualize and assess areas of HLA promiscuity, which is useful for general vaccine design. 10, 11 The identification of hotspots comprising peptides that bind multiple HLA alleles is of particular interest in the design of prophylactic vaccines that can protect the broader population against the pathogen in question.
Despite the seemingly completed hotspot discussion within infectious diseases, the hotspot phenomenon has recently resurfaced in the context of cancer immunotherapy and the development of personalized cancer treatment based on cancer neoepitopes (peptides originating from genomic alterations in cancer cells). 2, 3, 15 The reason for this reignited interest is twofold. It is, in part, due to the very low success rate in rational neoepitope identification studies, where only a minute proportion of the potential neoepitopes identified using state-of-the-art MHC affinity prediction tools are validated as immunogenic. Second, the huge advancements within the field of mass spectrometry (MS) have enabled a dramatic improvement in the identification of MHC-associated ligands. 1, 16 The inability to efficiently and with high accuracy identify immunogenic neoepitopes computationally indicates that binding affinity is far from enough to fully describe immunogenicity, which has spurred interest in examining how immunological hotspots could potentially be incorporated into neoepitope prediction. Hence, the hotspot feature has been given new life based on recent observations made in the analysis of MS data in several studies. 2, 3, 15 However, the conclusions made regarding the presence of MS ligand hotspots in studies so far are merely observations that some areas in protein sequences have a higher ligand density than others with the underlying rationale behind this observation not being fully examined.
To the best of our knowledge, this work is the first indepth attempt at systematically defining and investigating immunological hotspots to delineate whether hotspots created based on MS data could provide additional information in the prediction of peptide immunogenicity. Herein lies a comparison of MS data with MHC binding affinity prediction data to evaluate whether there is an element of ligand processing that should be considered in current prediction tools. Based on our analyses, we can conclude that MS-generated hotspots in the context of MHC class I molecules are largely captured by in silico HLA peptide binding predictions, suggesting that hotspot evaluation does not make a promising feature for incorporation into immunogenic peptide predictions. Moreover, our analyses also show that the signal of ligand processing contained within the MS data, although clearly present, has limited predictive power to discriminate between MS and in silico defined hotspots.
Materials and methods

Data
Mass spectrometry ligand data, the HLA alleles to which they were found to bind, and the source proteins were obtained from the immune epitope database and analysis resource (IEDB) (December 2016, Search criteria: Epitope = Linear epitope, Assays = Positive Assays Only and MHC Ligand Assays, Host = Humans, MHC Restriction = MHC class I, Disease = Any Disease. Further search filters: Mass Spectrometry as assay type) and Bassani-Sternberg et al. 2016 (MS data for the three HLA-typed patients Mel8, Mel15 and Mel16 only), respectively. 2 The MS ligand data were processed by filtering out ligands with an amino acid length < 8, > 13 and a predicted netMHCpan-3.0 percentile rank score of > 10%, leaving 56591 ligands. Source protein sequences were found in UniProt (TrEMBL and Swiss-Prot) and MS ligands were subsequently mapped to these source proteins. Ligands with rank score > 2% for which shorter nested ligands with stronger predicted binding existed were removed from the data. This resulted in a total of 56272 ligands mapped to 21606 proteins. The total ligand count and ligand mapping were recorded for each protein in the data set.
To improve the statistical power and to limit the analysis to single protein domains, the data set was filtered based on protein length and ligand density. Filtering was carried out to include only proteins with total ligand count of > 5 (3417 proteins), with a length of maximum 500 and minimum 50 amino acids and with a ligand density (ligand count divided by protein length) of > 0Á05. After filtering based on these criteria, the number of proteins in the data set was reduced to 567 with 12451 associated mapped ligands.
Methods
Hotspot potential. A score was assigned to each protein reflecting its hotspot potential. Here, a ligand count profile was first constructed by calculating the number of ligands overlapping each position in the protein, and a hotspot score (S_real) was calculated from the standard deviation of these scores over the protein sequence. Next, mean (S_ran) and standard deviation (SD_ran) background values were calculated from 1000 random count profiles obtained by mapping the ligands to random positions in the protein, ensuring that the S_ran values had a normal distribution (an example of this is illustrated in the Supplementary material, Fig. S1b ). Finally, a hotspot potential score was calculated as:
The distribution of hotspot potential standard deviations for random peptide mappings to the source proteins was visualized to be a normal distribution, ensuring the appropriate usage of the above z-score value Z_hotspot to define proteins with hotspots (data not shown). From this, a protein was defined to contain one or more hotspots if Z_hotspot > 1Á96 (value of the 97Á5th percentile of the normal distribution). Applying this threshold, 71 additional proteins were removed, leaving us with a final data set of 496 proteins covered by 11440 ligands, restricted by 73 different HLA molecules.
MS hotspots. Next, a term for the identification of the location of individual hotspots in the source proteins was defined. Here, a position was defined to potentially be part of a hotspot if its ligand count was higher than <S ran> + 2Á5*SD_ran, where <S_ran> and SD_ran were estimated as described in the previous section, and hotspots were identified as segments with five or more consecutive such hotspot residues.
In silico hotspots. In silico hotspots were identified in a similar way to the MS hotspots, using NetMHCpan-3.0 to define in silico peptides. The rank scores for all overlapping 8-13mers to the HLA molecules restricting the ligands contained within a given protein were predicted by sliding windows of 8-13 amino acids along the source protein sequences from the MS data set, and in silico peptides were identified as peptides with predicted rank score ≤ 1.
In silico peptides were next mapped back to the source proteins and in silico hotspots were identified based on the same criteria as described for the MS data with a hotspot threshold of the <S ran> + 2Á5*SD of 1000 randomly created peptide mappings and a hotspot length of a minimum stretch of five amino acids. Hotspots resulting from the mapping of MS ligands to the source proteins were defined to be predictable with the in silico data if at least 60% of the shortest of the two hotspots overlapped with the longer hotspot.
Processing potential. It was investigated whether a processing signal was present in the amino acid residues flanking ligands mapped to the above specified hotspot regions. This was done by calculating a position-specific scoring matrix. The signal was constructed from two different data sets, respectively:
1 The filtered MS data: This data set consisted of MS ligands mapped to the 496 proteins with hotspot potential > 1Á96 excluding ligands mapped to MS hotspots that were poorly predicted in silico. These data were kept out of the scoring matrix construction to allow an independent assessment of the difference in processing bias between hotspots identified by MS data only compared with hotspots identified by in silico data only. The amino acid background frequencies used to create the matrix were calculated based on all 567 proteins resulting from the first filtering criteria (high ligand density, length within a specific range and total ligand count). 2 External MS data: This data set of MS ligands was retrieved from the recently published article by Abelin et al. 3 . The entire data set consisted of unseen data and was, therefore, used to score the flanking regions of the ligands mapped to the MS hotspots that could be predicted, those that could only be poorly predicted and the peptides mapped to the in silico hotspots.
Two scoring matrices were created for each data set; one for the C-terminal and one for the N-terminal flanking region. C-and N-terminal scoring matrices were created based on the five-amino-acid flanking regions of the selected data set. The scoring matrices were constructed as log-odds matrices in which the score of each position was calculated based on log2(f/q), where f is the relative frequency of an amino acid at a given position including sequence weighting and pseudo-count correction for low counts (as described in ref. 17) , and q is the background frequency of the amino ª 2018 John Wiley & Sons Ltd, Immunology, 154, 407-417 acid in the selected background data set. The overall score of the ligand flanking regions was calculated by summing over the scores for each position using the constructed scoring matrices. Differences between the scores for the flanking regions of the ligands mapped to the MS hotspots and those mapped to the in silico hotspots were assessed using a twosided t-test for two independent samples of scores.
Results
We designed analyses to create an in-depth understanding of the properties defining HLA class I ligand-enriched areas in proteins, termed HLA I hotspots. More importantly, we were interested in discovering whether the occurrence of such hotspots could provide information beyond HLA binding in the prediction of HLA-restricted peptide immunogenicity. The analyses are divided into three parts: (i) Defining a measure to assess whether HLA hotspots are present in a given protein, and, if yes, how to map their location; (ii) investigating to what extent identified hotspots can be characterized by regions of increased HLA binding potential; and (iii) assuming that hotspots are defined by properties other than HLA binding, investigating the role of antigen processing in the context of MS hotspots.
Identification of MS ligand hotspots
The first issue faced when analysing the MS ligand hotspot phenomenon is the assessment of whether MS ligand hotspots exist in a given protein and, if yes, their precise location. To deal with this, we first defined a hotspot potential score reflecting the likelihood that a given protein contains regions where the presence of MS ligands is enriched beyond what could be expected by random. Next, we formulate a criterion to define the location of a hotspot in proteins with high hotspot potential score.
A set of MS HLA I eluted ligand data were extracted from IEDB and Sternberg et al., 2 respectively, and processed as described in the Materials and methods. The final data set consists of 12451 ligands, from 567 distinct proteins, restricted to 74 HLA molecules. The MS ligands were mapped to source proteins resulting in a profile for each source protein displaying the number of MS ligands overlapping each position in the protein sequence. Two such examples are displayed in Fig. 1 .
The hotspot potential score
From the MS ligand profiles, examples of which are shown in Figure 1 , a hotspot potential score was calculated for each protein by comparing the standard deviation of positional counts in a given protein with the expected standard deviation of positional counts obtained by randomly placing the ligands in the proteins 1000 times (for details, see Materials and methods). From this, a given protein was defined to contain hotspots if the hotspot potential score was greater than 1Á96 (97Á5th percentile of the normal distribution). Studying the hotspot potential values of the proteins within the MS ligand data set (Fig. 2 ) demonstrated that the vast majority (496 out of 567) had hotspot potential scores > 1Á96 with some proteins having scores > 20. The majority of proteins had a hotspot potential between 2 and 6 (see Supplementary material, Fig. S1 ) meaning that the ligand-enriched areas were clearly visually different from those created at random. For proteins with higher hotspot potentials, the ligandenriched peaks were even more pronounced (Fig. 3) .
In addition to defining the hotspot potential of proteins, individual hotspots were located in proteins based on a ligand count threshold defined from the ligand counts obtained by randomly placing the MS ligands mapped to the given protein (for details, see Materials and methods). Hotspots were then identified if there were segments with five or more consecutive residues with a ligand count surpassing the defined threshold. In general, we observe that proteins with high hotspot potentials have one or more clearly defined hotspots (see Fig. 3 ).
Determining the fraction of MS hotspots captured by in silico HLA peptide binding predictions
The HLA binding potential of the identified HLA I MS hotspots was next investigated; an analysis driven by the hypothesis that hotspots in protein sequences could simply be described as areas that are HLA I enriched (promiscuous areas) and, therefore, have a high HLA binding potential. To quantify the ability to predict MS hotspots with state-of-the-art in silico prediction tools, proteins with hotspot potential > 1Á96 were selected for prediction of in silico hotspots. In silico hotspots were next identified following the same procedure as for the MS hotspot identification; however, with peptides being defined as high-affinity predicted binders (predicted with netMHCpan-3.0) to the HLA I molecules restricting the H3BU31  H0YN88  G5E9R3  G5E9R0  Q30118  H0YKD8  J3KQ99  E9PPY6  P62318·1  NP_006271·1  NP_001005·1  NP_001027535·1  Q07820·3  XP_853154·1  NP_116270·1  Q96J88  P46781·3  F5H2Z3  HOY7G7  NP_001127965·1  Q9Y320·1  O95298·1  NP_061932·1  B7Z2R4  NP_003748·1  ADA59517·1  AAD34109·1  AAC27669·1  J3KMX5  P43308·1  H0Y6E7  H0YLJ3  K7EQJ5  P40429·2  P54368·3  Q5SQY0  E9PPV6  J3QR09  P08708·2  NP_003371·2  NP_072045·1  E9PM49  E9PKZ0  A6NL76  P31350·1  E9PS65  NP_001143·2  C9JU56  K7EJV9  J3QSB4  K7EM90  NP_064571·1  E7ERL0  Q9BQC6·1  AAI06897·1  F2Z388  M0R019  CAA29288·1  EAW49287·1  G3V1B3  P05387·1  F5H018  F8VS66  NP_057141·1  B8ZZK4  CAH56247·1  P49207·3  E9PQ34  F8W7C6  P62314·1  E9PP36  H3BT71  M0R181  F8VRZ4  NP_002098·1  NP_001122063·1  P12004·1  B4DV51  J3KTE4  E9PK54  M0R2D3  F8VWV9  F8VX09  F8W6P5  NP_958844·1  NP_001002·1  E9PLF4  B7Z4E3  E9PQQ4  K7EJ78  P62979·2  P62826·3  O95168·3  Q9NPE3·1  AAC28251·1  E9PN25  J3QL15  NP_001854·1  P35544·1 Here, all overlapping 8-13mers were included, and peptides with percentile rank score ≤ 1 were considered binders and used to identify the in silico hotspots.
The in silico predicted hotspots overlapped, in the majority of cases, with the MS hotspots (some examples are shown in Fig. 4) . However, according to our defined hotspot criterion, some proteins were observed to have MS hotspots only, whereas others had in silico hotspots only. Based on these observations, it was of interest to determine the fraction of MS hotspots that could be predicted based on the purely in silico predicted hotspots. Thus, we can quantify to what extent MS hotspots are characterized by regions of increased HLA binding potential by calculating the fraction of MS hotspots that overlap with an in silico hotspot. Here, we define an overlap between an MS and an in silico hotspot if > 60% of the residues in the shortest of the two hotspots are part of the longer hotspot. Performing this analysis, we find that 55% of the MS hotspots can be described in terms of HLA binding alone. The basis for this relatively low percentage was clarified when taking a closer look at the ligand mappings to the source proteins and, specifically, the proteins containing hotspots that could not be predicted in silico. The majority of these consisted of a substantial number of in silico peptides that overlapped the MS hotspots; however, the density of the in silico peptides in these areas of the sequence was not quite adequate to reach the defined hotspot threshold (examples are illustrated in Fig. 4b ,e-f,h-j). Hence, the in silico peaks overlapping the MS hotspots did not contain sufficient data to be defined as hotspots in terms of threshold and stretch of amino acids. In fact, only a single example of an MS hotspot appearing in a protein sequence stretch that was completely depleted in predicted in silico peptides was identified (Fig. 4k) . This MS hotspot appeared at position 102-112 in the protein AAH02900.2 to which a total of 16 MS ligands and 89 in silico peptides were mapped. These were restricted by nine HLA alleles of which seven were of the HLA supertype B27. Furthermore, only the 10mer ligand QRVASVMQEY, restricted by HLA-B27:05, HLA-B27:04, HLA-B27:03, HLA-B27:02 and HLA-B27:08, respectively, was present in the MS hotspot at position 102-112. Upon further inspection, this identified ligand was found to have a predicted percentile rank score just borderline > 1 (the score used to identify in silico peptides) for all the HLA alleles by which it was restricted.
Based on the relatively low percentage of predicted MS hotspots that we observed at the selected cut-off of 1Á96, we next asked to what extent this result was dependent upon the exact definition of the MS hotspots included in the analysis. Using a hotspot potential threshold of 1Á96 is somewhat arbitrary, and in Fig. 5 we show how the fraction of predictable MS hotspots varies as the hotspot potential threshold is increased (i.e. limiting the set of proteins included in the analysis). Fig. 5 shows a clear correlation between the fraction of MS hotspots that can be predicted using HLA binding prediction tools and the hotspot potential threshold (Spearman Correlation Coefficient = 0Á995), i.e. with a hotspot potential threshold of 12Á5, > 75% of MS hotspots are identified based on in silico predictions.
From this analysis, it was apparent that the defined hotspot potential of a given protein was an important factor in determining the fraction of hotspots that could be predicted in silico. These results are therefore indicative of the fact that the peptide enrichment in specific areas in protein sequences was to a high degree due to promiscuous HLA binding, which could be replicated in silico. This is corroborated by the aforementioned observation that MS hotspots that could not be predicted in silico overlapped with a considerable density of in silico peptides (Fig. 4b,e-f,h-j) . The in silico peaks overlapping the MS hotspots do not contain sufficient data to be defined as hotspots. This indicates an insufficiency in the number of HLA alleles included to describe the peptides in the source proteins, which is directly linked to the amount of data used for hotspot creation. Hence, despite the huge advancements in MS technology within recent years, data sufficiency and quality remain a crucial challenge for the adequate depiction of HLA I hotspots.
Processing potential of MS hotspots and in silico hotspots
Having quantified that HLA I hotspots are strongly dictated by the promiscuous HLA binding properties of peptide fragments contained within a given region of a protein sequence, we next investigated to what extent this observation could be complemented by signals related to antigen processing. To conduct this analysis, hotspots were divided into three distinct sets: a MS hotspots: Ligand-enriched areas in proteins according to the hotspot definition that only occur when mapping the MS data to the source proteins and not when predicted with in silico peptide mapping to the source proteins. First, we investigated whether there was a difference in ligand count in the hotspots in group (a) compared with group (c) (Fig. 6a) . Here, a significant difference was observed with the predictable MS hotspots containing more ligands than those only described by the MS data only. Furthermore, a significant difference was observed between the percentile rank scores in the two types of hotspots with MS ligands mapped to the predictable hotspots scoring significantly lower than those mapped to the hotspots that could not be predicted (Fig. 6b) . Both of these findings align with the earlier observations and confirm that hotspots that cannot be identified in silico in most cases are either characterized by few mapped MS ligands or by ligands restricted to HLA for which the binding prediction models have relatively poor predictive performance.
The above analysis elucidated that the majority of MS ligand hotspots can be identified with in silico prediction of HLA binding peptides that created areas with high HLA binding potential. However, when mapping in silico peptides to source proteins, in silico hotspots were observed that were not represented when mapping the MS data to the proteins (Fig. 7) as well as MS hotspots that were only poorly characterized by in silico predictions (see above). As a result, it was investigated whether this phenomenon was due to a processing potential of the MS ligands not contained in the in silico prediction models. Hence, we investigated whether a particular processing motif could be used to characterize the flanking regions of hotspots and whether this motif differed between ligands mapped to hotspots that were poorly predicted in silico and those that only occurred in the in silico data. C-terminal and N-terminal scoring matrices were created for MS ligands mapped to the 496 proteins with hotspot potential > 1Á96; however, with ligands mapped to poorly predicted MS hotspots removed (Fig. 8) . Scoring the MS and in silico hotspot N-and Cterminal flanking regions with these scoring matrices resulted in the MS hotspot flanking regions achieving a significantly higher score than those of the in silico hotspots (Fig. 9 ), so indicating a potential difference in the processing of the different types of hotspots.
Similar results were obtained when ligand flanking regions were scored with matrices created based on an external data set retrieved from the recently published article by Abelin et al. 3 (data not shown). The difference observed between the MS and in silico hotspots suggests the presence of a processing signal that should be further studied. Although the processing potential of MS hotspots could aid in clarifying the biological background for the observed findings, the analyses carried out herein could also indicate that the findings are simply due to an insufficient amount of data or insufficient representation of different HLA alleles in the prediction of hotspots. However, even with this being the case, it could be of interest to incorporate processing information into current prediction tools, potentially achieving superior performance in the prediction of HLA binding ligands.
Discussion
Much effort has been dedicated to the development of methods for accurate and cost-effective identification of immunogenic peptides. 1, 4, 7 The prediction of peptide binding affinity to MHC molecules is one such method, which has enabled the establishment of a clear correlation between MHC binding affinity and peptide immunogenicity. However, only a small proportion of the peptides measured or predicted to bind to an MHC molecule are immunogenic, underlining the fact that additional features are needed to efficiently and accurately describe peptide immunogenicity. 7, 8 Within recent years, this has, in concurrence with the huge advancements made within the field of MS, created an interest in examining whether a larger fraction of immunogenic peptides can be identified when incorporating knowledge about immunological hotspots of high epitope concentration. Studies on hotspots and the identification of these using prediction tools have particularly gathered speed in the field of cancer immunotherapy and the prediction of neoepitopes. 2, 10, 11 In this work, we have attempted to define a robust framework for the identification of MHC hotspots, and, based on this framework, sought to quantify to what degree such hotspots contain information beyond what is contained within predicted MHC binding promiscuity. We have done this by initially mapping all HLAbound peptides from the IEDB to the given source proteins and filtered peptides and proteins based on stringent criteria, allowing only proteins of biologically relevant length and peptides that are likely minimal epitopes to remain in the analysis. Subsequently, all possible 8-13mers restricted by the same HLA alleles as the MS ligands were predicted using NetMHCpan-3.0 and similarly mapped to the source proteins. From this, in silico hotspots were created, enabling an evaluation of the overlap between experimental and predicted hotspots. This peptide mapping showed a very high overlap between MS and in silico hotspots with the fraction of MS hotspots that could be predicted using HLA binding prediction tools increasing as a function of the hotspot potential. This said, some of the identified MS hotspots could not be re-created when mapping the in silico data according to the defined hotspot criterion. However, upon closer inspection, these un-predicted MS hotspots were mainly located in proteins with a low hotspot potential and typically appeared in areas with a density of in silico peptides leading to a hotspot potential of borderline significance. These un-predictable MS hotspots therefore consistently resulted from either a low MS hotspot potential and/or an insufficient number of HLA alleles included to predict peptides in silico; an observation directly linked to the amount of data used for hotspot creation. In summary, the results strongly suggest that in the context of MHC class I, the ligand enrichment observed in specific areas in protein sequences is due to promiscuous HLA binding which can, therefore, be replicated in silico. Given this, we conclude that hotspots are a simple result of promiscuous HLA binding and, therefore, also of limited complementary value for the identification of T cell epitopes.
Similar to the observation that some MS hotspots could not, at first, be re-created in silico, some proteins were observed to contain areas with in silico hotspots only. For this reason, it was investigated why these hotspots were lacking when mapping the MS data, and whether there was an element of ligand processing that could be identified separating these 'in silico only' hotspots from MS hotspots. To perform this analysis, scoring matrices were created based on the MS ligand data and subsequently used to score the signal of the flanking motifs for ligands mapped to MS hotspots and peptides mapped to in silico hotspots, respectively. This processing analysis showed a minimal signal indicating that current prediction algorithms could potentially be improved slightly by incorporating information on processing or simply by incorporating MS ligand data. However, even though we observe a processing signal differentiating MS hotspots from in silico-only hotspots, the relatively small amount of MS data available challenges any conclusions related to absence of hotspots in the analysis because absence of an MS hotspot could be a result of insufficient MS ligand sampling rather than the absence of an MS hotspot. Given these considerations, and the minimal discriminatory power of the processing signal to identify MS hotspots, we conclude that MHC class I hotspots, given the data included in the current study, are explained fully by MHC binding promiscuity.
This work has been limited to MHC class I ligands, and it remains to be seen if similar observations can be made for MHC class II, or if some cross-linking exists P-value:1·03797894115e-38 P-value:1·21293620635e-09 median = 0·118 median = -0·020 median = 0·029 median = 0·083 Figure 9 . The N-terminal (a) and C-terminal (b) flanking regions of the mass spectrometry (MS) hotspots that could not be predicted and the in silico hotspots were given a score using the scoring matrices created based on the 496 proteins with hotspot potential > 1Á96. The N-and Cterminal flanking regions of the ligands mapped to the MS hotspots achieved a significantly higher score than the flanking regions of the in silico peptides (P < 0Á001). between the two antigen presentation pathways making regions in proteins with enriched promiscuity for both MHC class I and class II binding more immunogenic.
